Brewin Dolphin Wealth Management’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
Other funds holding EDIT
CS
NAMA
Brewin Dolphin Wealth Management's EDIT Position: Q1 2022 in Review
Brewin Dolphin Wealth Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 150 shares — an estimated $4K sold.
Brewin Dolphin Wealth Management first reported a position in EDIT in Q3 2020 and held it in 6 quarters. The position peaked at $19.6K in Q4 2020. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.
- Brewin Dolphin Wealth Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
- Brewin Dolphin Wealth Management sold 150 Editas Medicine shares in Q1 2022, an estimated $4K.
- Brewin Dolphin Wealth Management first reported a position in Editas Medicine in Q3 2020 and held it in 6 quarters.
- Brewin Dolphin Wealth Management's Editas Medicine position peaked at $19.6K in Q4 2020.
- 256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.
Based on Brewin Dolphin Wealth Management's 13F filing for Q1 2022, filed 14 Nov 2022.